700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Annual Report to Security Holders
Investor Presentation
Insmed 2025 Financial Results and 2026 Revenue Projections
Insmed Updates on Phase 2b BiRCh Study and Discontinues CRSsNP Program
European Commission Approves as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
Insmed Reports Q3 2025 Results, BRINSUPRI™ Approved by FDA
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Free Writing Prospectus